Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.
about
Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study.A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors.High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.Effectiveness of very low doses of immunotherapy in advanced renal cell cancer.An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma.Pretreatment serum markers and lymphocyte response to interleukin-2 therapyHigh immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccinationProtracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II studySubcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trialSafety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinomaIs treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions.Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma.Metastatic renal carcinoma comprehensive prognostic systemPredictive models for the practical management of renal cell carcinoma.Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma.Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy.Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
P2860
Q33317794-1A04FC90-C3C7-43C8-995B-BC363AF93260Q35977818-9E48EC52-4FF9-49C7-8D08-53054466E217Q35979169-B810940B-21F9-4284-BEB5-C369188E17B2Q36071421-7ABBDCD7-9A2F-4AD5-965D-D6EEA90A6F08Q36081779-CF0A75BB-1F4B-4113-9858-D5CEA6AE86C8Q36115235-82BA353C-7899-4ADC-AC75-8EA5AC5BC4C9Q36316017-51464900-BCE7-4645-9082-9CAEA62B75BCQ36363721-C2F6CB56-8672-4863-9504-AA9D1998D6E4Q36430915-5518DC58-C8E4-49B8-9058-FA4E8933D2F9Q36614380-73EB3C41-15D4-45DC-96D0-1ED2B7C7EEEDQ36617894-D612580E-A400-4657-91BC-53795972D536Q36621785-861121AA-CC13-4A00-B46B-C7D4AD52D12AQ36621976-95E97106-7E23-4C3C-9E38-D0665E0A888DQ36673573-7D0897CD-4431-4269-8EE2-387997291E49Q36694752-3E504B23-8C98-4537-88F8-63B20D555DCDQ36696792-A2598105-3E69-40F9-B8C8-5C90E974F717Q36791584-A8F46490-52CE-4C2F-8752-BF8C51C2D99EQ37041069-2C738E19-9DF2-4723-A7A9-E4406DDBAC6CQ37354998-FBCF7FE8-505F-46A1-905A-C1873BBA8623Q37974504-5FEC1335-7278-454F-970C-833333C98002Q38610752-5982FA12-A361-4AA9-A859-739A9E084BD3Q47389809-95CA0C73-DB85-4BF1-9532-6E4B82CC927EQ47910619-C55C91C8-88C0-4588-BD09-7FD4027774ADQ54491390-A947004C-90F5-437F-BFE4-9231B41EA81F
P2860
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Prognostic factors for surviva ...... ith recombinant interleukin-2.
@en
type
label
Prognostic factors for surviva ...... ith recombinant interleukin-2.
@en
prefLabel
Prognostic factors for surviva ...... ith recombinant interleukin-2.
@en
P2093
P1433
P1476
Prognostic factors for surviva ...... ith recombinant interleukin-2.
@en
P2093
C R Franks
H Kirchner
J Atzpodien
P A Palmer
P304
P356
10.1093/OXFORDJOURNALS.ANNONC.A058239
P577
1992-06-01T00:00:00Z